The TL;DR.
Sermorelin is the first 29 amino acids of the hormone your hypothalamus naturally makes to tell your pituitary to release growth hormone. When you inject it, your pituitary responds the same way it would to your own body's signal — by releasing a pulse of GH. This is fundamentally different from injecting synthetic HGH directly.
With Sermorelin, your body's own feedback system stays in control. If GH goes too high, your hypothalamus releases somatostatin to slow things down. This makes it physiologically harder to overdose than with synthetic HGH. The trade-off is a lower ceiling — you can only get as much GH as your pituitary is capable of making.[3]
How it's actually used.
Before you start
- Draw baseline bloodwork. IGF-1, fasting glucose, HbA1c, fasting insulin, prolactin, cortisol (AM), TSH, free T4. See §8 for the full panel.
- Rule out active malignancy. GH and IGF-1 are mitogenic. Sermorelin is contraindicated in anyone with active or recent cancer without oncologist clearance.
- Confirm pituitary health. Sermorelin works by stimulating the pituitary. Pituitary adenoma or prior pituitary surgery — consult an endocrinologist first.
- Obtain a prescription. Sermorelin requires an Rx in the US. It is not legally sold for human use without one.
- Gather supplies. Bacteriostatic water, 1 mL insulin syringes (29–31 gauge, 5/16" needle), alcohol swabs, sharps container.
- Set a consistent injection time. Bedtime is strongly preferred. GH is naturally pulsed during slow-wave sleep — injecting at bedtime amplifies the largest natural pulse of the day.
Standard dosing
Sigalos et al. (2017) used 100 mcg TID and achieved a 50% IGF-1 increase over 134 days.[4] Community practice has trended toward higher single doses rather than three smaller doses. community
Reconstitution math (injectable)
Sermorelin arrives as lyophilized powder, typically in 2 mg, 5 mg, or 9 mg vials.
For a 5 mg vial · target 300 mcg per dose
- Add 2.5 mL of bacteriostatic water to the 5 mg vial.
- Final concentration: 5,000 mcg ÷ 2.5 mL = 2,000 mcg/mL (2 mcg/μL).
- For a 300 mcg dose: 300 ÷ 2,000 = 0.15 mL (15 units on a 100-unit insulin syringe).
- For a 200 mcg dose: 200 ÷ 2,000 = 0.10 mL (10 units).
Injection site guide
Sermorelin is administered subcutaneously — into the fat layer just beneath the skin, not into muscle. Rotate through:
- Abdomen — 2 inches from the navel, left or right side
- Outer thigh — middle third
- Lateral hip / love-handle area
A 7-site rotation (one per day of the week) is practical for daily dosing. Pinch the skin, insert at 45°, inject slowly, release the pinch before withdrawing.
Missed doses
- Missed by <12 hours: take the dose when you remember, then resume normal schedule.
- Missed by >12 hours: skip the missed dose entirely. Do not double-dose.
- Missed 3+ consecutive days: resume at the starting dose (100 mcg) for 1 week before returning to your usual dose.
Community consensus and real-world experience
In community discussions, the most commonly reported protocol is 200–300 mcg at bedtime, 5–7 nights per week, stacked with Ipamorelin at the same dose. Improved sleep quality is the most-reported first effect (weeks 2–4), followed by improved recovery and modest body composition changes at months 2–4. community Sermorelin alone produces more modest results than a sermorelin + GHRP stack — it is considered the "gentlest" entry point into GH-axis peptides.
Sleep quality is the first effect. Track it.
Epti correlates your nightly Sermorelin dose with sleep quality, HRV, and quarterly IGF-1 trends — so you can see what's working before the body-comp changes show up.
What to eat alongside.
Sermorelin elevates GH and IGF-1, both of which promote protein synthesis and lipolysis. Supporting nutrition matters.
Macronutrient adjustments
- Protein: 1.6–2.2 g/kg of body weight per day. IGF-1 drives muscle protein synthesis; adequate protein is required for translation into lean mass. well-established[5]
- Carbohydrates: Avoid large carb meals within 2 hours before injection. Insulin blunts GH release. The bedtime injection should be taken at least 90 minutes after the last meal. well-established[6]
- Fat: No specific restriction. Adequate dietary fat supports hormone production.
Micronutrient adjustments
- Zinc: 15–30 mg/day with food. Required for GH receptor signaling and IGF-1 production. Deficiency impairs response. emerging[7]
- Magnesium: 200–400 mg glycinate or threonate at bedtime. Supports slow-wave sleep architecture — when the largest natural GH pulse occurs. emerging
- Vitamin D: Maintain serum 25-OH vitamin D above 40 ng/mL. Low vitamin D is associated with reduced IGF-1 levels. emerging[8]
Synergistic supplements
- Ipamorelin: 100–300 mcg at same time as Sermorelin. Complementary mechanism (GHRP vs. GHRH) — synergistic GH pulse. community
- Melatonin: 0.5–1 mg, 30 min before bed. Deepens slow-wave sleep, amplifying the nocturnal GH pulse.
- L-Arginine: 3–5 g before bed. Inhibits somatostatin; may slightly enhance GH pulse. emerging
- Glycine: 3 g before bed. Improves sleep quality; may modestly increase GH.
Protective supplements
No specific protective supplements are required at standard doses. If fasting glucose rises above normal (see §8), consider berberine 500 mg with meals as a precaution. community
What can go wrong.
Reported side effects
Drug interactions
- Glucocorticoids (prednisone, dexamethasone) — suppress GH secretion; blunt Sermorelin response. Avoid concurrent use if possible.
- Insulin — hyperinsulinemia suppresses GH release; reduces Sermorelin efficacy. Inject fasted or 90+ min post-meal.
- Aromatase inhibitors — reduce estrogen → reduce IGF-1 expression. Expect blunted IGF-1 gains.[4]
- Synthetic HGH — redundant mechanism; pituitary receptor downregulation risk. Do not combine.
- Somatostatin analogues (octreotide) — directly antagonize Sermorelin's mechanism. Contraindicated.
Contraindications
- Active malignancy — GH/IGF-1 are mitogenic
- Active pituitary tumor or recent pituitary surgery
- Known hypersensitivity to sermorelin or formulation
- Diabetes / pre-diabetes — monitor glucose closely
- History of cancer (discuss with oncologist)
- Hypothyroidism — blunts GH response; optimize first
- Obstructive sleep apnea — treat OSA before starting
Red flags
- Sudden severe headache or vision changes (may indicate pituitary pressure)
- Signs of allergic reaction: hives, difficulty breathing, facial swelling
- Fasting glucose consistently above 126 mg/dL
- Significant joint swelling or carpal tunnel symptoms not resolving with dose reduction
- Any new lump or mass discovered during treatment
Pregnancy, lactation & fertility
No human data. Animal reproduction studies have not been conducted. Do not use during pregnancy or while breastfeeding. GH and IGF-1 play roles in reproductive function; no clinical data on Sermorelin's effect on fertility in humans.
Theoretical risks
- Long-term pituitary effects. Chronic stimulation of the GHRH receptor over decades is uncharacterized in healthy adults. Whether tolerance, fatigue, or adaptive changes occur is unknown.
What to combine it with.
Sermorelin + Ipamorelin
Sermorelin acts on the GHRH receptor; Ipamorelin acts on the ghrelin receptor (GHSR-1a). Together they produce a larger GH pulse than either alone — and Ipamorelin doesn't significantly raise cortisol or prolactin, unlike GHRP-2 or GHRP-6. community
Sermorelin + BPC-157
BPC-157 promotes angiogenesis and tendon/ligament healing through separate pathways from GH. Used by athletes and post-surgical patients seeking systemic recovery support plus local tissue repair. community
Sermorelin + Tesamorelin
Tesamorelin is a stabilized GHRH analogue with FDA approval for HIV-associated lipodystrophy. Some practitioners use both — most consider this redundant. community
Sermorelin + CJC-1295 (No DAC) + Ipamorelin
Commonly attempted, but mechanistically redundant — CJC-1295 No DAC and Sermorelin act on the same receptor with overlapping pharmacology. Most practitioners pick one. Included for completeness. community
Anti-pattern stacks — avoid
- Sermorelin + synthetic HGH. Redundant and counterproductive. Exogenous HGH suppresses pituitary function over time, negating Sermorelin's mechanism.
- Sermorelin + somatostatin analogues (octreotide). Direct pharmacological antagonism.
- Sermorelin + high-dose periworkout insulin. Insulin strongly suppresses GH release. Timing conflict reduces efficacy of both.
- Sermorelin + aromatase inhibitors if IGF-1 is the goal. Estrogen is required for full hepatic IGF-1 expression.
How to train on it.
Sermorelin produces gradual, subtle effects — not rapid recomposition. Users who expect dramatic changes in 4–8 weeks are typically disappointed.
Expected trajectory
Training adjustments
- Recovery capacity increases modestly. You may tolerate slightly higher training volume — don't dramatically ramp in the first 4 weeks.
- Sleep quality improvement (often the first reported benefit) enhances recovery. Prioritize 7–9 hours.
- Fasted morning training — consider a sermorelin injection 30–60 min before to amplify the GH pulse during exercise. community Advanced protocol.
- Avoid large carb meals within 2 hours before any injection.
Cut / recomp / bulk contexts
- Cut: Supports lean-mass preservation during a caloric deficit. High protein (2.0–2.4 g/kg) + resistance training is essential.
- Recomp: The most commonly reported use case. Gradual lean-mass gain with simultaneous fat loss at maintenance calories.
- Bulk: Less commonly used during aggressive bulking. GH promotes lean mass but also water retention. Some users cycle off during bulks.
How to store it.
Refrigerator preferred. Tolerable at room temp (up to 25 °C) for short periods (up to 30 days). Shelf life: typically 24 months from manufacture.
Refrigerate. Beyond-use date: 28 days. Do not freeze. Discard if cloudy, discolored, or particulate-containing.
Light & freeze sensitivity
- Light — moderately sensitive. Avoid prolonged UV exposure.
- Freeze — do not freeze reconstituted solution. Lyophilized powder can withstand freezing, but refrigeration is preferred.
Travel
- Transport in an insulated cooler bag with ice packs.
- Reconstituted vials should not exceed 4 hours at room temperature in transit.
- Carry in hand luggage — not checked baggage — to avoid temperature extremes.
- Unreconstituted powder is more travel-stable; reconstitute at destination if possible.
Sourcing & legal access
- United States. Rx required. Available from 503A compounding pharmacies with a valid prescription. Not FDA-approved; not legally sold for human use without an Rx.
- Cost-per-cycle (USD). Typically $80–$180 per month at standard dose via US compounding pharmacies.
- Global. UK MHRA: not licensed, may be available as "specials" via specialist prescriber. EU EMA: not approved, varies by member state. Canada: not Health Canada-approved; compounding pharmacy with Rx. Australia: TGA not approved; SAS Category B with prescriber application.
What to track.
Baseline panel
Mid-cycle panel (weeks 6–8)
Post-cycle panel (4 weeks after stopping)
Doctor handoff
vs. similar compounds.
| Sermorelin | CJC-1295 (No DAC) | Tesamorelin | Ipamorelin | MK-677 | |
|---|---|---|---|---|---|
| Half-life | 10–20 min | ~30 min | ~26 min | ~2 hours | ~24 hours |
| Mechanism | GHRH agonist | GHRH agonist (modified) | GHRH agonist (stabilized) | GHRP (ghrelin) | Oral GHSR |
| Pulse strength | Moderate | Moderate–high | High | Moderate | High (sustained) |
| Side-effect burden | Low | Low | Low–moderate | Very low | Moderate |
| Route | SC | SC | SC | SC | Oral |
| Legal status (US) | Rx compounding | Rx compounding | FDA-approved (Egrifta) | Rx compounding | Not approved |
When to pick Sermorelin
Sermorelin is the longest-standing GHRH analogue with the most established safety record. Choose Sermorelin when you want the most physiologically-natural GH pulse pattern and prescription access matters.
When to pick CJC-1295 (No DAC)
Functionally similar to Sermorelin with a slightly longer half-life. Has largely replaced Sermorelin in clinical practice for its longer duration. Pick this if longer per-injection duration matters.
When to pick Tesamorelin
The most-studied GHRH analogue with FDA approval for HIV-associated lipodystrophy. If cost is not a barrier, Tesamorelin is the better-evidenced choice for adults seeking GH-axis support.
When to pick MK-677
Pick MK-677 if oral dosing is preferred. Sermorelin produces a more physiological pulsatile pattern. MK-677 brings significantly more side effects (water retention, hunger, insulin resistance).
What the mechanism looks like.
Mechanism of action
Sermorelin is the biologically active N-terminal fragment (amino acids 1–29) of human GHRH. The full 44-amino-acid GHRH sequence is not required for biological activity; the first 29 residues contain the complete receptor-binding domain.
Sermorelin binds to the GHRH receptor (GHRHR), a G-protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Binding activates adenylyl cyclase → increases intracellular cAMP → activates protein kinase A → phosphorylates transcription factors → stimulates GH gene transcription and GH secretion. well-established
Sermorelin also stimulates pituitary gene transcription of hGH mRNA, increasing pituitary GH reserve over time — the basis of the "pituitary recrudescence" effect described by Walker (2006).[3] The pituitary becomes more capable of GH production with sustained sermorelin use.
The GH pulse triggered by sermorelin is subject to negative feedback from somatostatin, which is released from the hypothalamus in response to elevated GH and IGF-1. This feedback loop prevents pathological GH excess — a key safety advantage over exogenous HGH.
Pharmacokinetics
Active metabolites
No active metabolites identified. Sermorelin is degraded into inactive amino-acid fragments by plasma peptidases.
Human clinical trials
Adult clinical data is sparse — most published data is pediatric or extrapolated.
| Study | n | Duration | Population | Result |
|---|---|---|---|---|
| Sigalos et al. (2017) | 14 | 134 days | Hypogonadal men on TRT | +50% IGF-1 (p < 0.0001). Retrospective; part of GHRP/SERM combo |
| Walker (2006) | N/A | Editorial | Adults — review | Describes pituitary recrudescence mechanism |
| Multiple pediatric (1990s) | Hundreds | 12 months | Children with GHD | Significant height velocity increase |
Open questions
- What is the optimal dose and frequency for healthy adults seeking anti-aging or body-composition benefits?
- Does long-term Sermorelin use preserve pituitary function better than synthetic HGH?
- What is the true incidence of antibody formation in adults?
- Is there a meaningful difference in outcomes between Sermorelin and CJC-1295 (No DAC)?
Frequently asked.
Does Sermorelin increase IGF-1?
Yes. In the only published adult clinical study (Sigalos 2017), Sermorelin as part of a GHRP/SERM combination at 100 mcg TID increased IGF-1 by approximately 50% over 134 days (159.5 → 239.0 ng/mL, p<0.0001). The degree depends on baseline pituitary reserve, dose, and whether a GHRP is used.
How long does it take Sermorelin to work?
Most users report improved sleep quality within 2–4 weeks. Measurable IGF-1 increases typically appear at 6–8 weeks. Body composition changes are gradual — expect meaningful changes at months 2–4.
Can I use Sermorelin without a prescription?
In the United States, Sermorelin requires a prescription. It is not legally sold for human use without one. Research-grade Sermorelin sold online is not regulated for quality or purity and is not intended for human use.
Is Sermorelin the same as HGH?
No. Sermorelin tells your pituitary to make its own GH. Synthetic HGH replaces GH directly. The key difference is that Sermorelin's effects are regulated by your body's natural somatostatin feedback system, making overdose physiologically difficult.
What is the best time to inject Sermorelin?
Bedtime, at least 90 minutes after your last meal. GH is naturally released in pulses during slow-wave sleep — injecting at bedtime amplifies the largest natural GH pulse of the day. Avoid injecting after a carbohydrate-heavy meal — insulin suppresses GH release.
Can Sermorelin cause cancer?
There is no evidence that Sermorelin at standard doses causes cancer in healthy adults. However, GH and IGF-1 are mitogenic (they promote cell growth), and Sermorelin is contraindicated in anyone with active malignancy.
What is the difference between Sermorelin and CJC-1295?
Both are GHRH analogues that work through the same receptor. CJC-1295 (No DAC) has a slightly longer half-life (~30 min vs. 10–20 min). CJC-1295 (With DAC) has a dramatically longer half-life (~8 days) due to albumin binding. CJC-1295 (No DAC) has largely replaced Sermorelin in clinical practice; Sermorelin has the longer safety record.
Where it stands, by jurisdiction.
Last verified · May 17, 2026
Is Sermorelin for you?
What we cited.
- Esposito P. et al. (2003). PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 55(10):1279–1291. PMID: 14499707.
- US FDA. Drugs@FDA: GEREF (Sermorelin Acetate), NDA 019863. EMD Serono. Discontinued 2008.
- Walker R.F. (2006). Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 1(4):307–308. PMCID: PMC2699646.
- Sigalos J.T. et al. (2017). Growth hormone secretagogue treatment in hypogonadal men raises serum IGF-1 levels. Am J Mens Health. 11(6):1752–1757. PMID: 28830317.
- Morton R.W. et al. (2018). A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength. Br J Sports Med. 52(6):376–384. PMID: 28698222.
- Hartman M.L. et al. (1992). Augmented growth hormone secretory burst frequency and amplitude during a two-day fast. J Clin Endocrinol Metab. 74(4):757–765. PMID: 1548337.
- Nishi Y. et al. (1989). Effect of zinc supplementation on plasma IGF-1, IGFBP-3, and GH in children with growth retardation. Acta Paediatr Jpn. 31(3):247–252. PMID: 2530384.
- Ameri P. et al. (2013). Interactions between vitamin D and IGF-I: from physiology to clinical practice. Clin Endocrinol (Oxf). 79(4):457–463. PMID: 23826958.
- Prakash A., Goa K.L. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 12(2):139–157. PMID: 18031173.